Pretreatment total testosterone levels in patients with prostate cancer in the past two decades in Japan

Cancer Detection and Prevention

Volumn 31, Issue 2, 2007, Pages 149-153

  Sekine, Yoshitaka ^a   Ito, Kazuto ^a   Yamamoto, Takumi ^a   Nakazato, Haruki ^a   Shibata, Yasuhiro ^a   Hatori, Motoaki ^a   Suzuki, Kazuhiro ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Aging; Clinical parameters; Histological grade; Prostate cancer; Stage; Testosterone

Indexed keywords

TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIOIMMUNOASSAY; TESTOSTERONE BLOOD LEVEL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; RADIOIMMUNOASSAY; TESTOSTERONE;

EID: 34247648604     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2006.12.007     Document Type: Article

References (33)

1. Chan J.M., Stampfer M.J., and Giovannucci E.L. What causes prostate cancer? A brief summary of the epidemiology. Semin Cancer Biol 8 (1998) 263-273
2. Nakhla A.M., and Rosner W. Stimulation of prostate cancer growth by androgens and estrogens through the intermediacy of sex hormone-binding globulin. Endocrinology 137 (1996) 4126-4129
3. Andersson S.O., Adami H.O., Bergstrom R., and Wide L. Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer-a population-based case-control study. Br J Cancer 68 (1993) 97-102
4. British Prostate Study Group. Evaluation of plasma hormone concentrations in relation to clinical staging in patients with prostatic cancer. Br J Urol 51 (1979) 382-389
5. Hoisaeter P.A., Haukaas S., Bakke A., Hoiem L., Segadal E., and Thorsen T. Blood hormone levels related to stages and grades of prostatic cancer. Prostate 3 (1982) 375-381
6. Imamoto T., Suzuki H., Akakura K., Komiya A., Nakamachi H., Ichikawa T., et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J 48 (2001) 573-578
7. Massengill J.C., Sun L., Moul J.W., Wu H., McLeod D.G., Amling C., et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169 (2003) 1670-1675
8. Philip F., Trine B., Goran T., and Sophie D.F. No association of serum gonadal or pituitary hormones with prognostic parameters in stages T1 to T3 pNoMo prostate cancer. J Urol 168 (2002) 1188-1192
9. The Finnprostate Group. Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer. Prostate 39 (1999) 175-181
10. Jewett H.J. The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 2 (1975) 105-124
11. World Health Organization. International histological classification of tumours. Histological typing of prostate tumours (1980), World Health Organization, Geneva p. 17-23
12. Japanese Urological Association. General rule for clinical and pathological studies on prostate cancer. 3rd ed. (2001), Kanehara & Co., Ltd., Tokyo p. 40-9
13. Tanaka T., Huruta I., and Aihara T. Determination of total blood testosterone concentration by coated tube method, and basic examination on specificity of anti-testosterone antibody of the kit. Horumon To Rinsho 37 (1989) 961-964
14. Schatzl G., Madersbacher S., Thurridl T., Waldmuller J., Kramer G., Haitel A., et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47 (2001) 52-58
15. Monda J.M., Myers R.P., Bostwick D.G., and Oesterling J.E. The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration. Urology 46 (1995) 62-64
16. Hoffman M.A., Dewolf W.C., and Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer?. J Urol 163 (2000) 824-827
17. Eriksson A., and Carlstom K. Prognostic value of serum hormone concentrations in prostatic cancer. Prostate 13 (1988) 249-256
18. Morley J.E., Kaiser F.E., Perry III H.M., Patrick P., Morley P.M., Stauber P.M., et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 46 (1997) 410-413
19. Harman S.M., Metter E.J., Tobin J.D., Pearson J., and Blackman M.R. Baltimore longitudinal study of aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 86 (2001) 724-731
20. Iwamoto T., Yanase T., Koh E., Horie H., Baba K., Namiki M., et al. Reference ranges of serum total and free testosterone in Japanese male adults. Nippon Hinyokika Gakkai Zasshi 95 (2004) 751-760
21. San Francisco I.F., Regan M.M., DeWolf W.C., and Olumi A.F. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol 175 (2006) 1341-1346
22. Eaton N.E., Reeves G.K., Appleby P.N., and Key T.J. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 80 (1999) 930-934
23. Miller L.R., Partin A.W., Chan D.W., Bruzek D.J., Dobs A.S., Epstein J.I., et al. Influence of radical prostatectomy on serum hormone levels. J Urol 160 (1998) 449-453
24. Zhang P.L., Rosen S., Veeramachaneni R., Kao J., DeWolf W.C., and Bubley G. Association between prostate cancer and serum testosterone levels. Prostate 53 (2002) 179-182
25. Lukkarinen O., Hammond G.H., Kontturi M., and Vihko R. Peripheral and prostatic vein steroid concentrations in benign prostatic hypertrophy patients before and after removal of the adenoma. Scand J Urol Nephrol 14 (1980) 225-228
26. Iguchi T., Sumi M., and Tanabe S. Endocrine disruptor issues in Japan. Congenit Anom (Kyoto) 42 (2002) 106-119
27. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α & β. Endocrinology 138 (1997) 863-870
28. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139 (1998) 4252-4263
29. Nishihara T., Nishikawa J., Kanayama T., Dakeyama F., Saito K., Imagawa M., et al. Estrogenic activities of 517 chemicals by yeast two-hybrid assay. J Health Sci 46 (2000) 282-298
30. Sohoni P., and Sumpter J.P. Several environmental oestrogens are also anti-androgens. J Endocrinol 158 (1998) 327-339
31. Tariq S.H., Haren M.T., Kim M.J., and Morley J.R. Andropause: is the emperor wearing any cloths?. Rev Endo Metab Dis 6 (2005) 77-84
32. Diver M.J. Analytical and physiological factors affecting the interpretation of serum testosterone concentration in men. Ann Clin Biochem 43 (2006) 3-12
33. Gupta S.K., Lindemulder E.A., and Sathyan G. Modeling of circadian testosterone in healthy men and hypogonadal men. J Clin Pharmacol 40 (2000) 731-738